VEGFA and meningioma: Bevacizumab, which targets circulating VEGF has been reported in retrospective studies to increase progression-free survival (38, 39), while a phase II trial of sunitinib, a RTK inhibitor with antagonistic effect on VEGF receptor functioning demonstrated improved progression free survival in grade 2/3 meningiomas (Kaley 2015).